Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases: Case-control
- Status
- COMPLETED
- Phase
- N/A
Clinical Trials Related to Sanofi
Related studies linked through entity extraction aliases.
Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases: Inception Cohort
- Status
- COMPLETED
- Phase
- N/A
Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases:
- Status
- COMPLETED
- Phase
- N/A
Consensus Method to Evaluate the Conformity of Prescription of a Chemotherapy
- Status
- COMPLETED
- Phase
- N/A
Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)
- Status
- COMPLETED
- Phase
- PHASE3
Safety and Efficacy of Hectorol in Pediatric Patients With Chronic Kidney Disease Stage 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis
- Status
- TERMINATED
- Phase
- PHASE3
Fabry Disease in Cerebrovascular Disease
- Status
- UNKNOWN
- Phase
- N/A
Comparison of the Efficacy and Safety of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Insufficiently Controlled With Non-insulin Antidiabetic Therapy
- Status
- COMPLETED
- Phase
- PHASE3
Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Evaluation of the Fixed-dose Combination of Irbesartan/Atorvastatin in Type 2 Diabetic Patients Diagnosed With Hyperlipidemia and Hypertension
- Status
- COMPLETED
- Phase
- PHASE4
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
- Status
- COMPLETED
- Phase
- PHASE4
Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)
- Status
- COMPLETED
- Phase
- PHASE1
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
- Status
- COMPLETED
- Phase
- PHASE3
An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA)
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable
- Status
- COMPLETED
- Phase
- PHASE3
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan
- Status
- COMPLETED
- Phase
- PHASE3
Reduction to Preventive Doses of Enoxaparin After 3 to 6 Months of Treatment With Blood Thinners for Cancer-associated Blood Clots
- Status
- TERMINATED
- Phase
- N/A
Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs
- Status
- COMPLETED
- Phase
- PHASE3
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan
- Status
- COMPLETED
- Phase
- PHASE3